Anti-PD-L1/CD274 Rabbit Monoclonal Antibody for WB, IF/ICC, ELISA, Inhibition - Q9NZQ7

Core Product Specifications and Parameters

Biological Background: PD-L1/CD274 Function and Localization

• PD-L1 (CD274, B7-H1) is a type I transmembrane glycoprotein belonging to the B7 family of immune regulators.
• As a ligand for the inhibitory receptor PD-1, it suppresses T-cell receptor-mediated proliferation and cytokine production, playing a pivotal role in maintaining immune homeostasis and self-tolerance (PubMed:11015443, PubMed:28813410, PubMed:28813417). Related references: PMID:11015443 PMID:28813410 PMID:28813417
• Tumors hijack this pathway by overexpressing PD-L1, leading to T-cell exhaustion and immune evasion; therapeutic blockade of PD-1/PD-L1 interactions can restore anti-tumor immunity (PubMed:28813410, PubMed:28813417). Related references: PMID:28813410 PMID:28813417
• PD-L1 can also act as a transcription coactivator in the nucleus, promoting GSDMC-mediated pyroptosis under hypoxic conditions (PubMed:32929201). Related references: PMID:32929201
• Additionally, it may provide costimulatory signals via an unidentified receptor, enhancing IL-10 production in certain T-cell subsets (PubMed:10581077). Related references: PMID:10581077
• Subcellularly, PD-L1 localizes to the plasma membrane, endosomal compartments, and nucleus, and can be secreted.
• It is widely expressed in tissues including heart, muscle, placenta, and lung, and is upregulated on activated immune cells.
• Post-translational modifications include glycosylation and ubiquitination; structurally, it contains immunoglobulin V-like and C-like domains, a transmembrane helix, and a cytoplasmic tail.

Experimental Guidance and Technical Tips

• This antibody was generated using recombinant human PD-L1 protein as immunogen, suggesting reactivity with native and denatured forms; consider optimization for specific assay conditions.
• For western blotting (WB), PD-L1 migrates at an apparent molecular weight of approximately 33 kDa; include appropriate positive controls (e.g., PD-L1-overexpressing cell lysates) and verify detection in your sample system.
• In immunofluorescence (IF/ICC), expect membrane and possibly intracellular staining; validate subcellular localization under resting and stimulated conditions.
• For ELISA and inhibition/blocking applications, confirm the antibody’s ability to interfere with PD-L1/PD-1 binding using functional assays; note that activity may depend on epitope accessibility and antibody concentration.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is a premier one-stop provider of IVD raw materials, technical services, and consulting, supporting diagnostic manufacturers and laboratories from concept to clinic. This anti-PD-L1 antibody is part of our extensive immuno-oncology portfolio, where we offer validated antibody pairs, optimized monoclonal and polyclonal antibodies, and bulk ancillary reagents to accelerate your assay development. For researchers targeting immune checkpoint pathways, CamelBio also facilitates rare target raw-material sourcing and provides tailored technical support to bridge your procurement needs.